희귀질환 치료제 시장 : 치료법별, 치료 분야별, 투여 경로별, 질환별, 최종사용자별, 국가별, 지역별 - 세계 산업 분석, 시장 규모, 시장 점유율 및 예측(2026-2033년)

Rare Disease Therapeutics Market size was valued at US$ 174,990.83 Million in 2025, expanding at a CAGR of 14.1% from 2026 to 2033.

Rare disease therapeutics refer to specialized treatments developed for uncommon medical conditions, aimed at improving patient outcomes by targeting underlying disease mechanisms, slowing progression, and addressing limited treatment options while advancing precision and personalized medicine approaches. The Rare Disease Therapeutics market is experiencing growth as healthcare stakeholders increasingly focus on developing innovative treatments and improving access for patients with rare and orphan conditions. For instance, in 2026, findings reported in NIH Gov highlight that modern biomedical research supporting increasingly innovative treatment development is driven by evidence-based evaluation frameworks, where studies commonly demonstrate improvements in treatment efficacy ranging from approximately 20% to 40% over conventional therapeutic approaches depending on disease type and intervention model. This trend will drive innovation, investment, and broader access to rare disease treatments globally.

Rare Disease Therapeutics Market- Market Dynamics

Advancements in gene therapies to propel market demand

Advancements in gene therapies are rapidly reshaping the rare disease therapeutics landscape through the emergence of in vivo gene editing, improved vector engineering, and next-generation cell therapies that directly target disease-causing mutations. The industry is also witnessing a shift toward scalable and less complex delivery approaches, including non-viral platforms and in-body genetic modification techniques, improving accessibility and manufacturing efficiency.

Advancements in gene therapies are accelerating progress in the rare disease therapeutics market, with increasing development of targeted genetic treatments and approved therapies for monogenic disorders, improving treatment precision, expanding clinical success rates, and addressing previously untreatable conditions. For instance, in 2025, according to Catapult.org, highlights that advancements in gene therapies are accelerating in the UK, supported by a rapidly expanding advanced therapies ecosystem. Investment in the sector increased to around $1,223 million, up from approximately $971 million, reflecting growth in gene and cell therapy development pipelines. The report also indicates that the number of approved and reimbursed advanced therapies has risen to about 17, compared with 12 in the previous year, showing translation of gene-based innovations into clinical use. Therefore, gene therapies are rapidly transforming rare disease treatment through faster approvals and clinical impact.

Rare Disease Therapeutics Market- Segmentation Analysis:

The Global Rare Disease Therapeutics Market is segmented on the basis of Therapy Type, Therapeutic Area, Route Of Administration, Disease Type, End User, and Region.

Enzyme Replacement Therapy (ERT) holds a significant share in the Rare Disease Therapeutics market due to its widespread use in treating inherited metabolic and lysosomal storage disorders, along with its proven clinical efficacy in improving patient outcomes and disease m For instance, in 2024, research published by NIH.gov highlights that the growing use of enzyme replacement therapy (ERT) is significantly improving the management of lysosomal storage disorders and other rare genetic diseases. The study notes that lysosomal storage disorders affect nearly 1 in 5,000-7,000 live births globally, with over 70 identified disorders, while advancements in enzyme replacement therapy have improved treatment outcomes for diseases such as Gaucher, Fabry, and Pompe. Therefore, increasing ERT adoption is improving rare disease management and supporting market growth.

In terms of application, oncology holds a notable share in the rare disease therapeutics market, driven by the rising prevalence of rare cancers, increasing adoption of targeted therapies, advancements in precision medicine, and growing investment in orphan drug development. For instance, in 2026, data published by Cancer Research Org. UK highlights that oncology cases in the UK have risen significantly, with more than 403,000 people being diagnosed with cancer annually for the first time, equivalent to nearly 1,100 new cases every day or one diagnosis every 80 seconds. The UK records around 57,700 smoking-related cancer cases annually, with total cancer diagnoses projected to exceed 500,000 cases by 2040. Hence, rising oncology cases are driving growth in rare disease therapeutics.

Rare Disease Therapeutics Market- Geographical Insights

North America holds a prominent position in the rare disease therapeutics market, supported by a well-established healthcare system, research funding, and favorable regulatory frameworks for orphan drug development. For instance, in February 2025, data from the National Science Foundation (NSF) report highlights that U.S. research and development (R&D) continues to expand strongly, with total national R&D expenditures reaching about USD 940,000 million (preliminary estimate), up from USD 892,000 million, reflecting sustained momentum in the science and innovation ecosystem of the United States. Within this R&D landscape, funding is increasingly focused on high-impact biomedical research and therapeutics, supporting drug discovery, translational medicine, and advanced clinical development. Hence, rising R&D investment is driving rare disease therapeutics innovation in North America.

Apart from North America, Asia Pacific is expected to witness growth in the rare disease market, supported by rising healthcare investments, improving regulatory support, and an expanding patient base. For instance, in 2025, data from the OECD's org highlights that Japan is experiencing a rapidly expanding patient base primarily driven by its aging population structure. The share of people aged 65 years and above is estimated at around 29% of the total population, one of the highest among OECD countries, reflecting a demographic shift toward elderly care demand. Japan's life expectancy is ~84-85 years with healthcare spending around 10-11% of GDP, driving long-term chronic care demand. Therefore, Japan's aging population is driving rare disease market growth.

The Rare Disease Therapeutics market in Switzerland is supported by its pharmaceutical ecosystem, advanced healthcare infrastructure, and continuous investment in biomedical research. In March 2026, Roche inaugurated a new research home for the Institute of Human Biology in Basel as part of its major site investment, strengthening its biomedical research capabilities focused on advanced human model systems and accelerating drug discovery and development through AI and organoid technologies. Therefore, Switzerland's ecosystem is driving rare disease research and innovation growth.

Rare Disease Therapeutics Market- Competitive Landscape:

The Rare Disease Therapeutics market features a blend of high concentration among leading global pharmaceutical companies and a dynamic ecosystem of emerging biotech firms. Key players such as Pfizer Inc., Sanofi S.A., Novartis AG, Roche Holding AG, and Takeda Pharmaceutical Company Limited significant revenue shares, particularly in biologics and gene therapies. Competition is primarily driven by innovation rather than price, with companies focusing on superior clinical outcomes, patient-centric solutions, and strong real-world evidence to secure premium positioning. In January 2026, Novartis AG announced an expansion of its rare disease therapeutics portfolio through continued investment in advanced gene therapy and RNA-based research programs, strengthening its pipeline for treating inherited and ultra-rare genetic disorders. Therefore, continuous innovation and investment will sustain market growth momentum.

Recent Developments:

In June 2025, Ultragenyx Pharmaceutical Inc. announced continued advancement of its rare disease gene therapy pipeline through expanded clinical development and manufacturing collaboration initiatives, strengthening its focus on developing innovative treatments for genetic and ultra-rare disorders.

In January 2025, Roche Holding AG expanded its rare disease therapeutics pipeline through continued advancement of its gene therapy and precision medicine programs, focusing on accelerating clinical development of innovative biologics for ultra-rare genetic disorders.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RARE DISEASE THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

• Pfizer Inc.
• Sanofi S.A.
• Novartis AG
• F. Hoffmann-La Roche AG
• Takeda Pharmaceutical Company Limited
• Bristol Myers Squibb Company
• Amgen Inc. (includes Horizon Therapeutics)
• Biogen Inc.
• AstraZeneca PLC (includes Alexion Rare Disease unit)
• Vertex Pharmaceuticals Incorporated
• BioMarin Pharmaceutical Inc.
• Regeneron Pharmaceuticals, Inc.
• UCB S.A.
• Ipsen S.A.
• Sarepta Therapeutics, Inc.
• Ultragenyx Pharmaceutical Inc.
• PTC Therapeutics, Inc.
• Others

GLOBAL RARE DISEASE THERAPEUTICS MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2020 - 2033

• Small Molecule Drugs
• RNA-based Therapies
• Monoclonal Antibodies
• Gene Therapy
• Enzyme Replacement Therapy (ERT)
• Others

GLOBAL RARE DISEASE THERAPEUTICS MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2020 - 2033

• Immunology
• Cardiovascular
• Oncology
• Others

GLOBAL RARE DISEASE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033

• Injectable
• Oral
• Others

GLOBAL RARE DISEASE THERAPEUTICS MARKET, BY DISEASE TYPE- MARKET ANALYSIS, 2020 - 2033

• Sickle Cell Disease (SCD)
• Duchenne Muscular Dystrophy (DMD)
• Gaucher Disease
• Fabry Disease
• Spinal Muscular Atrophy (SMA)
• Others

GLOBAL RARE DISEASE THERAPEUTICS MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033

• Specialty Centers
• Hospitals
• Others

GLOBAL RARE DISEASE THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• The Netherlands
• Sweden
• Russia
• Poland
• Denmark
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• South Korea
• Australia
• Indonesia
• Thailand
• Philippines
• Taiwan
• Vietnam
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Turkey
• Algeria
• Egypt
• Iran
• Qatar
• Rest of MEA

Table of Contents

1. Rare Disease Therapeutics Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Rare Disease Therapeutics Market Snippet by Therapy Type
  • 2.1.2. Rare Disease Therapeutics Market Snippet by Therapeutic Area
  • 2.1.3. Rare Disease Therapeutics Market Snippet by Route Of Administration
  • 2.1.4. Rare Disease Therapeutics Market Snippet by Disease Type
  • 2.1.5. Rare Disease Therapeutics Market Snippet by End User
  • 2.1.6. Rare Disease Therapeutics Market Snippet by Country
  • 2.1.7. Rare Disease Therapeutics Market Snippet by Region
• 2.2. Competitive Insights

3. Rare Disease Therapeutics Key Market Trends

• 3.1. Rare Disease Therapeutics Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Rare Disease Therapeutics Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Rare Disease Therapeutics Market Opportunities
• 3.4. Rare Disease Therapeutics Market Future Trends

4. Rare Disease Therapeutics Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Rare Disease Therapeutics Market : Impact of Escalating Geopolitical Tensions

• 5.1. Impact of COVID-19 Pandemic
• 5.2. Impact of Russia-Ukraine War
• 5.3. Impact of Middle East Conflicts

6. Rare Disease Therapeutics Market Landscape

• 6.1. Rare Disease Therapeutics Market Share Analysis, 2025
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Rare Disease Therapeutics Market - By Therapy Type

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Therapy Type, 2025 & 2033 (%)
  • 7.1.2. Small Molecule Drugs
  • 7.1.3. RNA-based Therapies
  • 7.1.4. Monoclonal Antibodies
  • 7.1.5. Gene Therapy
  • 7.1.6. Enzyme Replacement Therapy (ERT)
  • 7.1.7. Others

8. Rare Disease Therapeutics Market - By Therapeutic Area

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Therapeutic Area, 2025 & 2033 (%)
  • 8.1.2. Immunology
  • 8.1.3. Cardiovascular
  • 8.1.4. Oncology
  • 8.1.5. Others

9. Rare Disease Therapeutics Market - By Route Of Administration

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By Route Of Administration, 2025 & 2033 (%)
  • 9.1.2. Injectable
  • 9.1.3. Oral
  • 9.1.4. Others

10. Rare Disease Therapeutics Market - By Disease Type

• 10.1. Overview
  • 10.1.1. Segment Share Analysis, By Therapeutic Area, 2025 & 2033 (%)
  • 10.1.2. Sickle Cell Disease (SCD)
  • 10.1.3. Duchenne Muscular Dystrophy (DMD)
  • 10.1.4. Gaucher Disease
  • 10.1.5. Fabry Disease
  • 10.1.6. Spinal Muscular Atrophy (SMA)
  • 10.1.7. Others

11. Rare Disease Therapeutics Market - By End User

• 11.1. Overview
  • 11.1.1. Segment Share Analysis, By End User, 2025 & 2033 (%)
  • 11.1.2. Specialty Centers
  • 11.1.3. Hospitals
  • 11.1.4. Others

12. Rare Disease Therapeutics Market - By Geography

• 12.1. Introduction
  • 12.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
• 12.2. North America
  • 12.2.1. Overview
  • 12.2.2. Rare Disease Therapeutics Key Manufacturers in North America
  • 12.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 12.2.4. North America Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  • 12.2.5. North America Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
  • 12.2.6. North America Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
  • 12.2.7. North America Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  • 12.2.8. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.2.9. U.S.
    • 12.2.9.1. Overview
    • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.2.9.3. U.S. Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.2.9.4. U.S. Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.2.9.5. U.S. Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.2.9.6. U.S. Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.2.9.7. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.2.10. Canada
    • 12.2.10.1. Overview
    • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.2.10.3. Canada Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.2.10.4. Canada Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.2.10.5. Canada Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.2.10.6. Canada Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.2.10.7. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
• 12.3. Europe
  • 12.3.1. Overview
  • 12.3.2. Rare Disease Therapeutics Key Manufacturers in Europe
  • 12.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 12.3.4. Europe Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  • 12.3.5. Europe Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
  • 12.3.6. Europe Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
  • 12.3.7. Europe Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  • 12.3.8. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.3.9. Germany
    • 12.3.9.1. Overview
    • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.3.9.3. Germany Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.3.9.4. Germany Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.3.9.5. Germany Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.3.9.6. Germany Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.3.9.7. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.3.10. UK
    • 12.3.10.1. Overview
    • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.3.10.3. UK Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.3.10.4. UK Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.3.10.5. UK Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.3.10.6. UK Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.3.10.7. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.3.11. France
    • 12.3.11.1. Overview
    • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.3.11.3. France Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.3.11.4. France Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.3.11.5. France Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.3.11.6. France Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.3.11.7. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.3.12. Italy
    • 12.3.12.1. Overview
    • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.3.12.3. Italy Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.3.12.4. Italy Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.3.12.5. Italy Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.3.12.6. Italy Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.3.12.7. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.3.13. Spain
    • 12.3.13.1. Overview
    • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.3.13.3. Spain Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.3.13.4. Spain Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.3.13.5. Spain Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.3.13.6. Spain Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.3.13.7. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.3.14. The Netherlands
    • 12.3.14.1. Overview
    • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.3.14.3. The Netherlands Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.3.14.4. The Netherlands Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.3.14.5. The Netherlands Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.3.14.6. The Netherlands Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.3.15. Sweden
    • 12.3.15.1. Overview
    • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.3.15.3. Sweden Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.3.15.4. Sweden Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.3.15.5. Sweden Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.3.15.6. Sweden Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.3.15.7. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.3.16. Russia
    • 12.3.16.1. Overview
    • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.3.16.3. Russia Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.3.16.4. Russia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.3.16.5. Russia Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.3.16.6. Russia Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.3.16.7. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.3.17. Poland
    • 12.3.17.1. Overview
    • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.3.17.3. Poland Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.3.17.4. Poland Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.3.17.5. Poland Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.3.17.6. Poland Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.3.17.7. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.3.18. Denmark
    • 12.3.18.1. Overview
    • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.3.18.3. Denmark Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.3.18.4. Denmark Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.3.18.5. Denmark Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.3.18.6. Denmark Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.3.18.7. Denmark Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.3.19. Rest of Europe
    • 12.3.19.1. Overview
    • 12.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.3.19.3. Rest of the Europe Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.3.19.4. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.3.19.5. Rest of the Europe Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.3.19.6. Rest of the Europe Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.3.19.7. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
• 12.4. Asia Pacific (APAC)
  • 12.4.1. Overview
  • 12.4.2. Rare Disease Therapeutics Key Manufacturers in Asia Pacific
  • 12.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 12.4.4. APAC Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  • 12.4.5. APAC Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
  • 12.4.6. APAC Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
  • 12.4.7. APAC Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  • 12.4.8. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.4.9. China
    • 12.4.9.1. Overview
    • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.4.9.3. China Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.4.9.4. China Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.4.9.5. China Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.4.9.6. China Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.4.9.7. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.4.10. India
    • 12.4.10.1. Overview
    • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.4.10.3. India Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.4.10.4. India Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.4.10.5. India Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.4.10.6. India Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.4.10.7. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.4.11. Japan
    • 12.4.11.1. Overview
    • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.4.11.3. Japan Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.4.11.4. Japan Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.4.11.5. Japan Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.4.11.6. Japan Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.4.11.7. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.4.12. South Korea
    • 12.4.12.1. Overview
    • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.4.12.3. South Korea Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.4.12.4. South Korea Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.4.12.5. South Korea Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.4.12.6. South Korea Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.4.12.7. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.4.13. Australia
    • 12.4.13.1. Overview
    • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.4.13.3. Australia Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.4.13.4. Australia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.4.13.5. Australia Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.4.13.6. Australia Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.4.13.7. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.4.14. Indonesia
    • 12.4.14.1. Overview
    • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.4.14.3. Indonesia Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.4.14.4. Indonesia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.4.14.5. Indonesia Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.4.14.6. Indonesia Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.4.14.7. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.4.15. Thailand
    • 12.4.15.1. Overview
    • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.4.15.3. Thailand Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.4.15.4. Thailand Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.4.15.5. Thailand Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.4.15.6. Thailand Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.4.15.7. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.4.16. Philippines
    • 12.4.16.1. Overview
    • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.4.16.3. Philippines Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.4.16.4. Philippines Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.4.16.5. Philippines Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.4.16.6. Philippines Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.4.16.7. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.4.17. Taiwan
    • 12.4.17.1. Overview
    • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.4.17.3. Taiwan Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.4.17.4. Taiwan Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.4.17.5. Taiwan Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.4.17.6. Taiwan Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.4.17.7. Taiwan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.4.18. Vietnam
    • 12.4.18.1. Overview
    • 12.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.4.18.3. Vietnam Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.4.18.4. Vietnam Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.4.18.5. Vietnam Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.4.18.6. Vietnam Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.4.18.7. Vietnam Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.4.19. Rest of APAC
    • 12.4.19.1. Overview
    • 12.4.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.4.19.3. Rest of APAC Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.4.19.4. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.4.19.5. Rest of APAC Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.4.19.6. Rest of APAC Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.4.19.7. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
• 12.5. Latin America (LATAM)
  • 12.5.1. Overview
  • 12.5.2. Rare Disease Therapeutics Key Manufacturers in Latin America
  • 12.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 12.5.4. LATAM Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  • 12.5.5. LATAM Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
  • 12.5.6. LATAM Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
  • 12.5.7. LATAM Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  • 12.5.8. LATAM Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.5.9. Brazil
    • 12.5.9.1. Overview
    • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.5.9.3. Brazil Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.5.9.4. Brazil Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.5.9.5. Brazil Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.5.9.6. Brazil Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.5.9.7. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.5.10. Mexico
    • 12.5.10.1. Overview
    • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.5.10.3. Mexico Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.5.10.4. Mexico Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.5.10.5. Mexico Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.5.10.6. Mexico Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.5.10.7. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.5.11. Argentina
    • 12.5.11.1. Overview
    • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.5.11.3. Argentina Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.5.11.4. Argentina Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.5.11.5. Argentina Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.5.11.6. Argentina Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.5.11.7. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.5.12. Colombia
    • 12.5.12.1. Overview
    • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.5.12.3. Colombia Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.5.12.4. Colombia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.5.12.5. Colombia Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.5.12.6. Colombia Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.5.12.7. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.5.13. Rest of LATAM
    • 12.5.13.1. Overview
    • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
• 12.6. Middle East and Africa
  • 12.6.1. Overview
  • 12.6.2. Rare Disease Therapeutics Key Manufacturers in Middle East and Africa
  • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 12.6.4. Middle East and Africa Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
  • 12.6.5. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
  • 12.6.6. Middle East and Africa Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
  • 12.6.7. Middle East and Africa Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
  • 12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.6.9. Saudi Arabia
    • 12.6.9.1. Overview
    • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.6.10. United Arab Emirates
    • 12.6.10.1. Overview
    • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.6.11. Israel
    • 12.6.11.1. Overview
    • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.6.11.3. Israel Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.6.11.4. Israel Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.6.11.5. Israel Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.6.11.6. Israel Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.6.11.7. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.6.12. Turkey
    • 12.6.12.1. Overview
    • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.6.12.3. Turkey Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.6.12.4. Turkey Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.6.12.5. Turkey Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.6.12.6. Turkey Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.6.12.7. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.6.13. Algeria
    • 12.6.13.1. Overview
    • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.6.13.3. Algeria Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.6.13.4. Algeria Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.6.13.5. Algeria Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.6.13.6. Algeria Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.6.13.7. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.6.14. Egypt
    • 12.6.14.1. Overview
    • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.6.14.3. Egypt Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.6.14.4. Egypt Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.6.14.5. Egypt Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.6.14.6. Egypt Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.6.14.7. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.6.15. Iran
    • 12.6.15.1. Overview
    • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.6.15.3. Iran Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.6.15.4. Iran Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.6.15.5. Iran Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.6.15.6. Iran Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.6.15.7. Iran Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.6.16. Qatar
    • 12.6.16.1. Overview
    • 12.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.6.16.3. Qatar Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.6.16.4. Qatar Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.6.16.5. Qatar Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.6.16.6. Qatar Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.6.16.7. Qatar Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 12.6.17. Rest of MEA
    • 12.6.17.1. Overview
    • 12.6.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.6.17.3. Rest of MEA Market Size and Forecast, By Therapy Type, 2020 - 2033 (US$ Million)
    • 12.6.17.4. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 12.6.17.5. Rest of MEA Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
    • 12.6.17.6. Rest of MEA Market Size and Forecast, By Disease Type, 2020 - 2033 (US$ Million)
    • 12.6.17.7. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)

13. Key Vendor Analysis- Rare Disease Therapeutics Industry

• 13.1. Competitive Benchmarking
  • 13.1.1. Competitive Dashboard
  • 13.1.2. Competitive Positioning
• 13.2. Company Profiles
  • 13.2.1. Pfizer Inc.
  • 13.2.2. Sanofi S.A.
  • 13.2.3. Novartis AG
  • 13.2.4. F. Hoffmann-La Roche AG
  • 13.2.5. Takeda Pharmaceutical Company Limited
  • 13.2.6. Bristol Myers Squibb Company
  • 13.2.7. Amgen Inc. (includes Horizon Therapeutics)
  • 13.2.8. Biogen Inc.
  • 13.2.9. AstraZeneca PLC (includes Alexion Rare Disease unit)
  • 13.2.10. Vertex Pharmaceuticals Incorporated
  • 13.2.11. BioMarin Pharmaceutical Inc.
  • 13.2.12. Regeneron Pharmaceuticals, Inc.
  • 13.2.13. UCB S.A.
  • 13.2.14. Ipsen S.A.
  • 13.2.15. Sarepta Therapeutics, Inc.
  • 13.2.16. Ultragenyx Pharmaceutical Inc.
  • 13.2.17. PTC Therapeutics, Inc.
  • 13.2.18. Others

14. 360 Degree AnalystView

15. Appendix

• 15.1. Research Methodology
• 15.2. References
• 15.3. Abbreviations
• 15.4. Disclaimer
• 15.5. Contact Us